(Q38445535)

3 September 2017

0 references

1 reference

title

Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials (English)

1 reference

3 September 2017

1 reference

1 reference

Fausto Petrelli

1

1 reference

3 September 2017

Mary Cabiddu

2

1 reference

3 September 2017

Andrea Coinu

3

1 reference

3 September 2017

Karen Borgonovo

4

1 reference

3 September 2017

Mara Ghilardi

5

1 reference

3 September 2017

Veronica Lonati

6

1 reference

3 September 2017

Sandro Barni

7

1 reference

3 September 2017

language of work or name

English

0 references

publication date

28 April 2015

1 reference

Breast Cancer Research and Treatment

3 September 2017

published in

1 reference

3 September 2017

volume

151

1 reference

3 September 2017

issue

2

1 reference

3 September 2017

page(s)

251-259

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-015-3405-4

3 September 2017

exact match

0 references

cites work

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3405-4

10.1007/S10549-015-3405-4

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1002828992

0 references

1 reference